> The FDA hit Acacia Pharma with a complete response letter. Acacia suffered the setback after the FDA found fault with the contract manufacturer of the active ingredient in post-operative nausea and vomiting drug Barhemsys. Statement
> Therachon bought GLyPharma Therapeutic to add a synthetic GLP-2 analog targeting short bowel syndrome to its pipeline. Release
> BerGenBio dosed the first patient in the second stage of its Keytruda combination trial. Statement
> Oryzon dosed the first patient in a phase 2a trial of people who suffer episodes of aggressiveness. The basket trial will also look at the drug, LSD1-MAOB inhibitor vafidemstat, in patients with other neurodegenerative and psychiatric disorders. Release
> U.K. regulators cleared NeuroVive to run a trial of NAD+ modulator KL1333. Statement